$1.44 Million in Sales Expected for Clearside Biomedical Inc (NASDAQ:CLSD) This Quarter
Brokerages expect Clearside Biomedical Inc (NASDAQ:CLSD) to post $1.44 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Clearside Biomedical’s earnings. The highest sales estimate is $4.10 million and the lowest is $80,000.00. Clearside Biomedical posted sales of $50,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 2,780%. The firm is scheduled to report its next earnings results on Wednesday, August 5th.
According to Zacks, analysts expect that Clearside Biomedical will report full year sales of $8.31 million for the current year, with estimates ranging from $4.33 million to $16.04 million. For the next year, analysts anticipate that the business will report sales of $10.86 million, with estimates ranging from $1.00 million to $30.14 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. Clearside Biomedical had a negative return on equity of 165.19% and a negative net margin of 293.61%. The business had revenue of $4.10 million during the quarter, compared to analyst estimates of $4.00 million.
In other Clearside Biomedical news, CEO George M. Lasezkay sold 32,150 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $1.99, for a total value of $63,978.50. Following the sale, the chief executive officer now directly owns 311,100 shares in the company, valued at $619,089. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.10% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of CLSD. Carmignac Gestion acquired a new stake in Clearside Biomedical in the first quarter valued at $3,367,000. Morgan Stanley acquired a new stake in Clearside Biomedical in the first quarter valued at $440,000. Oxford Asset Management LLP acquired a new stake in Clearside Biomedical in the fourth quarter valued at $382,000. Oxford Financial Group Ltd. acquired a new stake in Clearside Biomedical in the first quarter valued at $156,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Clearside Biomedical during the fourth quarter worth about $257,000. Institutional investors own 25.74% of the company’s stock.
Shares of CLSD traded down $0.05 during midday trading on Thursday, hitting $1.88. 215,841 shares of the stock were exchanged, compared to its average volume of 751,876. Clearside Biomedical has a 52-week low of $0.56 and a 52-week high of $4.13. The stock has a fifty day simple moving average of $1.99 and a 200 day simple moving average of $2.25. The firm has a market cap of $85.25 million, a P/E ratio of -4.09 and a beta of 1.07. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.71 and a current ratio of 1.71.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Recommended Story: What is the Consumer Price Index (CPI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.